Abstract
BackgroundGCA may be an interleukin-6 (IL-6) driven disease and IL-6 blockade is emerging as an exciting therapy of IL-6.1 We measured serial IL-6 levels in new patients with GCA treated...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.